Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Shares Outstanding (Weighted Average) (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $77.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 751.02% to $77.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $77.8 million through Dec 2025, up 751.02% year-over-year, with the annual reading at $77.8 million for FY2025, 751.02% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $77.8 million at Plus Therapeutics, down from $107.4 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $107.4 million in Q3 2025, with the low at $142733.0 in Q1 2024.
  • Average Shares Outstanding (Weighted Average) over 5 years is $15.5 million, with a median of $2.5 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) tumbled 93.85% in 2024, then surged 10105.58% in 2025.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $2.1 million in 2021, then dropped by 18.25% to $1.8 million in 2022, then skyrocketed by 79.45% to $3.1 million in 2023, then soared by 191.08% to $9.1 million in 2024, then skyrocketed by 751.02% to $77.8 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $77.8 million, $107.4 million, and $48.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.